Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: OCGN stock price vs CHKP: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at CHKP's multiple
Needs CHKP P/S.
Implied fair value · at OCGN's multiple
Needs OCGN P/S.
Metric by metric
Live quote
Price unavailable
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: OCGN FY 2025 (ended Dec 31, 2025) · CHKP FY 2025 (ended Dec 31, 2025).
Trendline
Seven fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
OCUGEN, INC. · implied price per share
Bear
-$0.05
Base
-$0.06
Bull
-$0.07
CHECK POINT SOFTWARE TECHNOLOGIES LTD. · implied price per share
Bear
$44.43
Base
$52.28
Bull
$60.12
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
-2.37x
1.68x
Net debt / EBITDA
Leverage against operating earnings
-0.15x
2.99x
Cash and equivalents
Liquid reserves on the balance sheet
$19.47M
$1.80B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
IOVANCE BIOTHERAPEUTICS, INC.
OCGN vs IOVA
bluebird bio, Inc.
OCGN vs BLUE
BioNTech SE
OCGN vs BNTX
Moderna, Inc.
OCGN vs MRNA
Legend Biotech Corp
OCGN vs LEGN
Arcturus Therapeutics Holdings Inc.
OCGN vs ARCT
Palo Alto Networks Inc
OCGN vs PANW
Fortinet, Inc.
OCGN vs FTNT
Zscaler, Inc.
OCGN vs ZS
CrowdStrike Holdings, Inc.
OCGN vs CRWD
$28.79M
$4.83B
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe OCGN can rapidly scale revenue while reversing its deeply negative margins and improving quality scores, then avoid relying on CHKP-implied valuation alone because the current -95.3% downside signal is being driven by fundamental weakness rather than just market sentiment.
OCGN trades at $1.51 versus an implied price of $0.07 from the P/S comparison, indicating -95.3% downside. The gap is driven by OCGN's extremely rich sales multiple versus CHKP's far more mature and profitable profile.
Supporting Metrics
